Search results
This High-Flying Stock Just Announced More Good News: Time to Buy?
The Motley Fool via AOL· 4 days agoTrue, the company still has to ace phase 3 studies before it can launch these products. In that sense, the stock does remain risky. It will need to generate ...
3 Reasons to Buy Moderna Stock
Motley Fool via Yahoo Finance· 5 days agoThe 10 stocks that made the cut...2005... if you invested $1,000 at the time of our recommendation, you’d have $741,362!* Stock Advisor provides...
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Motley Fool via Yahoo Finance· 3 days agoTherefore, while both stocks are a good option for those seeking exposure to biotech, Viking is the...
StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)
ETF DAILY NEWS· 10 hours agoInvestment analysts at StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a note issued to investors on Thursday. The brokerage ...
3 Stocks With Mouthwatering Dividends You Can Buy Right Now | The Motley Fool
The Motley Fool· 5 days agoNot all dividend stocks are equal. Three Motley Fool contributors have found stocks with mouthwatering dividends that you can buy right now. Here's why ...
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX)
ETF DAILY NEWS· 8 hours agoForte Biosciences, Inc. (NASDAQ:FBRX – Get Free Report) saw some unusual options trading on Wednesday. Investors purchased 30,205 call options on the company. This is an increase of 1,663% compared ...
Why Moderna Stock Is a No-Brainer Buy Right Now
The Motley Fool via AOL· 3 days agoThe average price-to-sales multiple for the biotech industry is around 6.4. I don't think the valuation is unreasonable, though, for one simple reason: The company is...it's ...
Adrian Lewis Sells 14,721 Shares of Inchcape plc (LON:INCH) Stock
ETF DAILY NEWS· 13 hours agoInchcape plc (LON:INCH – Get Free Report) insider Adrian Lewis sold 14,721 shares of the stock in a transaction on Monday, June 10th. The stock was sold ...
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Motley Fool via Yahoo Finance· 4 days agoThe...2005... if you invested $1,000 at the time of our recommendation, you’d have $740,688!* Stock...
Should You Buy the Dip on Compass Pathways Stock? | The Motley Fool
The Motley Fool· 1 day agoOn that note, Compass Pathways (CMPS 7.04%) stock fell by 9% on June 4, and the stock is down 20%...
